Company intelligence / Profile preview

Läkarexpressen

Sweden

Ownership: Private
Development stage: Other

Overview

Läkarexpressen AB develops and provides AI-driven digital health tools in collaboration with patients and researchers. The company has participated as a sponsor or collaborator in clinical studies, such as those involving venous leg ulcer care with Granulox and type 2 diabetes treatment. Its focus appears to be on supporting Swedish healthcare delivery through innovative technology.

Therapeutic areas: OtherCardiovascularEndocrinology
Modalities: Digital health toolsAI-based healthcare support
Industry: Digital Health Medical Devices

Partnerships

Lund UniversityRegion SkåneRegion HallandVästra Götalandsregionen

Beyond the preview

Go deeper on Läkarexpressen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Läkarexpressen.

Explore the full profile